- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06581575
Um estudo de fase 2 para avaliar JCXH-105, uma vacina contra herpes zoster baseada em SrRNA
Um estudo de fase 2, randomizado, triplo-cego e com controle ativo para avaliar a segurança e a imunogenicidade de uma vacina experimental contra herpes zoster (HZ), JCXH-105, em indivíduos saudáveis ≥ 50 anos de idade
The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles).
Subjects will be randomized to receive either JCXH-105 or Shingrix.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This Phase 2 study plans to enroll a total of 460 subjects.
This will be an active-controlled study in healthy male and/or female subjects 50 years of age or older. Subjects will be randomized 1:1 to receive either JCXH-105 or Shingrix. The study vaccine will be administered in two doses approximately 2 months apart. The subject will receive a single intramuscular (IM) injection of JCXH-105 or Shingrix on Day 1 (Dose 1) and again on Day 61 ± 7 days (Dose 2). For each subject, Dose 1 and Dose 2 are the same study vaccine based on randomization on Day 1. A total of 460 subjects will be enrolled into this trial and vaccinated with either JCXH-105 (n=230) or Shingrix (n=230).
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85704
- Noble Clinical Research
-
-
California
-
Long Beach, California, Estados Unidos, 90805
- Long Beach Research Institute
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60652
- DM Clinical Research - Chicago
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68114
- Quality Clinical Research
-
-
New Jersey
-
Jersey City, New Jersey, Estados Unidos, 07306
- DM Clinical Research - New Jersey
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29407
- Delricht Research
-
-
Texas
-
Prosper, Texas, Estados Unidos, 75078
- Delricht Research
-
Sugar Land, Texas, Estados Unidos, 77478
- DM Clinical Research - Sugarland
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Key Inclusion Criteria:
- Sex: Male or female; female subjects may be of childbearing potential, of nonchildbearing potential, or postmenopausal.
- Age: ≥ 50 years of age at screening.
- Status: Healthy subjects.
- Subjects must agree to not be vaccinated with any HZ vaccine while participating in this study.
- Subjects must agree to not be vaccinated with any RNA-based vaccines (e.g., Spikevax, Comirnaty, etc.) 30 days before Dose 1 through 30 days after Dose 2 (a 4-month period).
Key Exclusion Criteria:
- Subjects with a history of HZ within the past 10 years or current diagnosis of HZ.
- Previous vaccination against HZ.
- Subjects with any respiratory illness deemed clinically relevant by the Investigator within the past month OR hospitalization >24 hours for any reason within the past month prior to the first vaccine administration (JCXH-105 or Shingrix).
- Subjects who are acutely ill or febrile with body temperature ≥ 38.0º Celsius/100.4º Fahrenheit 72 hours prior to or at the Screening visit or on Day 1 pre-dose. Subjects meeting this criterion may be rescheduled within an allowable window with approval from the Sponsor.
- Subjects with history or current diagnosis of congenital or acquired immunodeficiency/immunocompromising/immunosuppressive conditions, asplenia, or recurrent severe infections. Certain immune-mediated conditions (e.g., Hashimoto thyroiditis) that are well controlled and stable are allowed.
- Subjects with history of myocarditis or pericarditis, or with AEs (including anaphylaxis and severe hypersensitivity) after mRNA vaccination that are in nature and severity beyond the common expected AEs and necessitating medical intervention.
- Subjects who received any non-live vaccine within 14 days prior to Day 1 (first dose of JCXH-105 or Shingrix).
- Subjects who received within 28 days prior to Day 1 (first dose of JCXH-105 or Shingrix): (1) Any live vaccine, (2) Immunomodulators or immune-suppressive medication, (3) Granulocyte or granulocyte-macrophage colony-stimulating factor, (4) Three or more consecutive days of systemic corticosteroids. Note: subjects on stable-dose steroid replacement (for chronic disease such as iatrogenic deficiency) of prednisone ≤10 mg/day or equivalent are allowed and (5) Other investigational agents or devices.
- Subjects receiving systemic antiviral therapy.
- Subjects with a positive screening test for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, anti-human HIV-1 and 2 antibodies, or syphilis.
- Subjects with a positive screening test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Investigational Product
Participants randomized to this arm will be given the investigational product (JCXH-105). |
IM injection |
|
Comparador Ativo: Active Control
Participants randomized to this arm will be given the FDA approved Shingrix. |
IM injection |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
SAE Frequency
Prazo: Day 1 - Day 241 (Week 34)
|
Frequency of SAEs characterized by type, severity, duration, and relationship to the vaccine recorded from Day 1 post-vaccine administration through follow-up completion. |
Day 1 - Day 241 (Week 34)
|
|
Solicited local reaction frequency
Prazo: Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)
|
Occurrence of solicited local injection site reactions characterize by frequency, severity, and duration within 7 days after each vaccine administration. |
Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)
|
|
Solicited systemic reaction frequency
Prazo: Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)
|
Occurrence of solicited systemic reactions characterize by frequency, severity, and duration within 7 days after each vaccine administration. |
Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)
|
|
AE Frequency
Prazo: Day 1 - Day 241 (Week 34)
|
Adverse events (AEs) including unsolicited AEs and any AEs leading to discontinuation of study vaccine or withdrawal from the study, characterized by frequency, severity, duration, and relationship to the vaccine from Day 1 post-vaccine administration through follow-up completion. |
Day 1 - Day 241 (Week 34)
|
|
AESIs Frequency
Prazo: Day 1 - Day 241 (Week 34)
|
AESIs characterized by frequency, severity, duration, and relationship to the vaccine from Day 1 post-vaccine administration through follow-up completion. |
Day 1 - Day 241 (Week 34)
|
|
Medically Attended AE Frequency
Prazo: Day 1 - Day 241 (Week 34)
|
Medically attended AEs (MAAEs) characterized by frequency, severity, duration, and relationship to the vaccine from Day 1 post-vaccine administration through follow-up completion. |
Day 1 - Day 241 (Week 34)
|
|
Immune-Mediated Adverse Events of Special Interest Frequency
Prazo: Day 1 - Day 241 (Week 34)
|
Immune-mediated adverse events of special interest (imAESIs) characterized by frequency, severity, duration, and relationship to the vaccine (JCXH-105 or Shingrix) recorded from Day 1 post-vaccine administration through follow-up completion. |
Day 1 - Day 241 (Week 34)
|
|
gE-Specific CD4+ T cell Response Rate
Prazo: Day 1 - Day 89 (Week 13)
|
Response Rate is defined at the percentage of subjects with ≥ 2 folds increase of gE-specific CD4+ T cells expressing 2 or more markers of activation (IFN-γ, IL-2, TNFα, and CD40L) in PBMCs analyzed with flow cytometry with ICS on Day 89 as compared to baseline (Day 1 pre-dose). |
Day 1 - Day 89 (Week 13)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cellular immunogenicity of JCXH-105
Prazo: Day 1 - Day 241 (Week 34)
|
Frequency of glycoprotein E (gE)-specific CD4+ T cells expressing 2 or more markers of activation (IFN-γ, IL-2, TNF-α, and CD40L) in PBMCs analyzed by flow cytometry with ICS on Day 29, Day 89, and Day 241 as compared to baseline (Day 1 pre-dose). |
Day 1 - Day 241 (Week 34)
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cellular Immunogenicity of JCXH-105
Prazo: Day 1 - Day 241 (Week 34)
|
Frequency of gE-specific CD8+ T cells expressing 2 or more markers of activation (IFN-γ, IL-2, TNF-α, and CD40L) in PBMCs analyzed by flow cytometry on Day 29, Day 89, and Day 241 as compared to baseline (Day 1 pre-dose). |
Day 1 - Day 241 (Week 34)
|
|
Humoral immunogenicity of JCXH-105
Prazo: Day 1 - Day 241 (Week 34)
|
Changes in serum of anti-gE-specific antibody geometric mean titers (GMTs) analyzed with enzyme-linked immunosorbent assay (ELISA) on Day 29, Day 89, and Day 241 as compared to baseline (D1 pre-dose). |
Day 1 - Day 241 (Week 34)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- JCXH-105-021
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .